MARKET DISCOVERY
Initial Concept
Our initial target disease and proof-of-concept is thrush, where 5-10% of cases reoccur after each antifungal course. Our approach aims to provide long-term relief that current strategies cannot deliver.
Stakeholders
We wish to speak to Pharma/biotech companies who are looking for solutions to early stage therapeutic discovery and who are interested in diversifying current technology while keeping up to date with innovations in treatment and prevention of infections.